On Target Laboratories LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From On Target Laboratories LLC
Sponsors are receiving information requests and complete response letters as a result of the agency’s transition plan, which was made in response to the Genus v. FDA ruling. The decision's aftershocks could reshape the landscape for a number of products, attorney says.
Keeping Track: US FDA Clears On Target’s Cytalux, VBI’s PreHevbrio; Keytruda Grows In Adjuvant Melanoma
The latest FDA approval news and highlights from the Pink Sheet’s US FDA Performance Tracker.
On Target Laboratories’ Cytalux (pafolacianine) is now approved for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.
News and highlights of applications submitted for US FDA approval, from the Pink Sheet’s FDA Performance Tracker
- Radiopharmaceuticals, Contrast Agents
- Other Names / Subsidiaries
- On Target Laboratories, Inc.